– 1894 . 4. Robert C Long GV Brady B . Nivolumab in previously untreated melanoma without BRAF mutation . N Engl J Med 2015 ; 372 : 320 – 330 . 5. Topalian SL Sznol M McDermott DF . Survival durable tumor remission, and long
Search Results
Rogerio A. Lilenbaum and Leora A. Horn
mutations are the most common genetic alterations, and ALK, ROS1 , and RET rearrangements and BRAF mutations are also targetable. Less than half of NSCLCs of adenocarcinoma histology have no known alterable genotype,” explained Rogerio A. Lilenbaum, MD
Anthony J. Olszanski
and ipilimumab versus ipilimumab in untreated melanoma . N Engl J Med 2015 [e-pub ahead of print] . 13. Robert C Long GV Brady B . Nivolumab in previously untreated melanoma without BRAF mutation . N Engl J Med 2015 ; 372 : 320
Axel Grothey
Rossius L . Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients [abstract] . Eur J Cancer
Al B. Benson III
selection and prognosis: KRAS mutation determination (now extended RAS assessment) before considering anti-epidermal growth factor receptor (EGFR) therapy; BRAF mutation status as a prognostic tool, and microsatellite instability analysis, particularly
Robert I. Haddad
inhibitor selumetinib induced iodine incorporation in patients with BRAF -mutations. 6 Figure 1 Progression free survival (PFS; primary endpoint). From Schoffski P, et al: J Clin Oncol 2012;30(15 suppl):Abstract 5508 7 ; Reprinted with permission
Megan P. Hitchins, Estela Dámaso, Rocio Alvarez, Lisa Zhou, Yajing Hu, Marcio A. Diniz, Marta Pineda, Gabriel Capella, Rachel Pearlman, and Heather Hampel
2010 ; 12 : 498 – 504 . 20489114 20. Nakagawa H , Nagasaka T , Cullings HM , Efficient molecular screening of Lynch syndrome by specific 3′ promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high
David S. Ettinger, Dara L. Aisner, Douglas E. Wood, Wallace Akerley, Jessica Bauman, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D'Amico, Thomas J. Dilling, Michael Dobelbower, Ramaswamy Govindan, Matthew A. Gubens, Mark Hennon, Leora Horn, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Rogerio Lilenbaum, Jules Lin, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Sandip P. Patel, Karen Reckamp, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, James Stevenson, Scott J. Swanson, Kurt Tauer, Stephen C. Yang, Kristina Gregory, and Miranda Hughes
% of patients with lung adenocarcinoma who are typically current or former smokers. 65 – 67 BRAF mutations typically do not overlap with EGFR mutations or ALK rearrangements. 65 , 68 The NCCN panel recommends testing for BRAF mutations based
Allan C. Halpern and Sanjay K. Mandal
. 17. Kefford RF Mann GJ . Is there a role for genetic testing in patients with melanoma? Curr Opin Oncol 2003 ; 15 : 157 – 161 . 18. Uribe P Andrade L Gonzalez S . Lack of association between BRAF mutation and MAPK ERK activation
Timothy Lindsay and Sujana Movva
600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours . J Clin Pathol 2009 ; 62 : 613 – 616 . 33. Hostein I Faur N Primois C . BRAF mutation status in
